Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

Alessio Giuseppe Morganti; Francesco Cellini; Samantha Mignogna; Gilbert Da Padula; Luciana Caravatta; Francesco Deodato; Vincenzo Picardi; Gabriella Macchia; Savino Cilla; Milly Buwenge; Liberato Di Lullo; Maria Antonietta Gambacorta; Mario Balducci; Gian Carlo Mattiucci; Rosa Autorino; Vincenzo Valentini

doi:10.2217/fon.15.350

Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

Alessio Giuseppe Morganti, Francesco Cellini^*, Samantha Mignogna, Gilbert Da Padula, Luciana Caravatta, Francesco Deodato, Vincenzo Picardi, Gabriella Macchia, Savino Cilla, Milly Buwenge, Liberato Di Lullo, Maria Antonietta Gambacorta, Mario Balducci, Gian Carlo Mattiucci, Rosa Autorino, Vincenzo Valentini

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo in rivista

2 Citazioni (Scopus)

Abstract

Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.

Lingua originale	English
pagine (da-a)	779-787
Numero di pagine	9
Rivista	Future Oncology
Volume	12
DOI	https://doi.org/10.2217/fon.15.350
Stato di pubblicazione	Pubblicato - 2016

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Camptothecin
Cancer Research
Chemoradiotherapy
Colorectal Neoplasms
Female
Fluorouracil
Humans
Leucovorin
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Oncology
Phase II
Radiotherapy Dosage
Treatment Outcome
bevacizumab
chemo-sensitization
low-dose radiotherapy
metastatic colorectal cancer
multidisciplinary integrated treatments

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.2217/fon.15.350

Altri file e collegamenti

Cita questo

Morganti, A. G., Cellini, F., Mignogna, S., Padula, G. D., Caravatta, L., Deodato, F., Picardi, V., Macchia, G., Cilla, S., Buwenge, M., Lullo, L. D., Gambacorta, M. A., Balducci, M., Mattiucci, G. C., Autorino, R., & Valentini, V. (2016). Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study. Future Oncology, 12, 779-787. https://doi.org/10.2217/fon.15.350

@article{b2d98b7dcec94445a1ed3fa176405065,

title = "Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study",

abstract = "Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Cancer Research, Chemoradiotherapy, Colorectal Neoplasms, Female, Fluorouracil, Humans, Leucovorin, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Oncology, Phase II, Radiotherapy Dosage, Treatment Outcome, bevacizumab, chemo-sensitization, low-dose radiotherapy, metastatic colorectal cancer, multidisciplinary integrated treatments, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Cancer Research, Chemoradiotherapy, Colorectal Neoplasms, Female, Fluorouracil, Humans, Leucovorin, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Oncology, Phase II, Radiotherapy Dosage, Treatment Outcome, bevacizumab, chemo-sensitization, low-dose radiotherapy, metastatic colorectal cancer, multidisciplinary integrated treatments",

author = "Morganti, {Alessio Giuseppe} and Francesco Cellini and Samantha Mignogna and Padula, {Gilbert Da} and Luciana Caravatta and Francesco Deodato and Vincenzo Picardi and Gabriella Macchia and Savino Cilla and Milly Buwenge and Lullo, {Liberato Di} and Gambacorta, {Maria Antonietta} and Mario Balducci and Mattiucci, {Gian Carlo} and Rosa Autorino and Vincenzo Valentini",

year = "2016",

doi = "10.2217/fon.15.350",

language = "English",

volume = "12",

pages = "779--787",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

AU - Morganti, Alessio Giuseppe

AU - Cellini, Francesco

AU - Mignogna, Samantha

AU - Padula, Gilbert Da

AU - Caravatta, Luciana

AU - Deodato, Francesco

AU - Picardi, Vincenzo

AU - Macchia, Gabriella

AU - Cilla, Savino

AU - Buwenge, Milly

AU - Lullo, Liberato Di

AU - Gambacorta, Maria Antonietta

AU - Balducci, Mario

AU - Mattiucci, Gian Carlo

AU - Autorino, Rosa

AU - Valentini, Vincenzo

PY - 2016

Y1 - 2016

N2 - Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.

AB - Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bevacizumab

KW - Camptothecin

KW - Cancer Research

KW - Chemoradiotherapy

KW - Colorectal Neoplasms

KW - Female

KW - Fluorouracil

KW - Humans

KW - Leucovorin

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Oncology

KW - Phase II

KW - Radiotherapy Dosage

KW - Treatment Outcome

KW - bevacizumab

KW - chemo-sensitization

KW - low-dose radiotherapy

KW - metastatic colorectal cancer

KW - multidisciplinary integrated treatments

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bevacizumab

KW - Camptothecin

KW - Cancer Research

KW - Chemoradiotherapy

KW - Colorectal Neoplasms

KW - Female

KW - Fluorouracil

KW - Humans

KW - Leucovorin

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Oncology

KW - Phase II

KW - Radiotherapy Dosage

KW - Treatment Outcome

KW - bevacizumab

KW - chemo-sensitization

KW - low-dose radiotherapy

KW - metastatic colorectal cancer

KW - multidisciplinary integrated treatments

UR - http://hdl.handle.net/10807/92456

UR - http://www.futuremedicine.com/loi/fon

U2 - 10.2217/fon.15.350

DO - 10.2217/fon.15.350

M3 - Article

SN - 1479-6694

VL - 12

SP - 779

EP - 787

JO - Future Oncology

JF - Future Oncology

ER -

Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo